The pleiotropic effects of paricalcitol: Beyond bone-mineral metabolism

Abstract

Secondary hyperparathyroidism (SHPT) is a common complication in patients with chronic kidney disease (CKD) that is characterised by elevated parathyroid hormone (PTH) levels and a series of bone-mineral metabolism anomalies. In patients with SHPT, treatment with paricalcitol, a selective vitamin D receptor activator, has been shown to reduce PTH levels with minimal serum calcium and phosphorus variations. The classic effect of paricalcitol is that of a mediator in mineral and bone homeostasis. However, recent studies have suggested that the benefits of treatment with paricalcitol go beyond PTH reduction and, for instance, it has a positive effect on cardiovascular disease and survival. The objective of this study is to review the most significant studies on the so-called pleiotropic effects of paricalcitol treatment in patients with CKD.

Keywords: Aterosclerosis; Atherosclerosis; Calcificación vascular; Dialysis; Diálisis; Hiperparatiroidismo secundario; Hormona paratiroidea; Parathyroid hormone; Proteinuria; Secondary hyperparathyroidism; Transplant; Trasplante; Vascular calcification; Vitamin D; Vitamina D.